270 related articles for article (PubMed ID: 17275980)
41. Re: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
Cartwright R; Cardozo L
J Urol; 2007 Feb; 177(2):796-7; author reply 797. PubMed ID: 17222687
[No Abstract] [Full Text] [Related]
42. Botulinum toxin in the management of lower urinary tract dysfunction: contemporary update.
Cruz F; Silva C
Curr Opin Urol; 2004 Nov; 14(6):329-34. PubMed ID: 15626874
[TBL] [Abstract][Full Text] [Related]
43. Botulinum toxin injection for lower urinary tract dysfunction.
Kuo YC; Kuo HC
Int J Urol; 2013 Jan; 20(1):40-55. PubMed ID: 22571329
[TBL] [Abstract][Full Text] [Related]
44. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
Grosse J; Kramer G; Jakse G
BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
[TBL] [Abstract][Full Text] [Related]
45. Use of Botulinum Toxin in Urologic Diseases.
Chermansky CJ; Chancellor MB
Urology; 2016 May; 91():21-32. PubMed ID: 26777748
[TBL] [Abstract][Full Text] [Related]
46. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.
Karsenty G; Elzayat E; Delapparent T; St-Denis B; Lemieux MC; Corcos J
J Urol; 2007 Mar; 177(3):1011-4. PubMed ID: 17296399
[TBL] [Abstract][Full Text] [Related]
47. Emerging role of botulinum toxin in the management of voiding dysfunction.
Smith CP; Chancellor MB
J Urol; 2004 Jun; 171(6 Pt 1):2128-37. PubMed ID: 15126771
[TBL] [Abstract][Full Text] [Related]
48. Botulinum toxin type A for the treatment of lower urinary tract disorders.
Yokoyama T; Chancellor MB; Oguma K; Yamamoto Y; Suzuki T; Kumon H; Nagai A
Int J Urol; 2012 Mar; 19(3):202-15. PubMed ID: 22220916
[TBL] [Abstract][Full Text] [Related]
49. Histologic features in the urinary bladder wall affected from neurogenic overactivity--a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A.
Compérat E; Reitz A; Delcourt A; Capron F; Denys P; Chartier-Kastler E
Eur Urol; 2006 Nov; 50(5):1058-64. PubMed ID: 16517054
[TBL] [Abstract][Full Text] [Related]
50. In the human urothelium and suburothelium, intradetrusor botulinum neurotoxin type A does not induce apoptosis: preliminary results.
Kessler TM; Khan S; Panicker JN; Elneil S; Brandner S; Fowler CJ; Roosen A
Eur Urol; 2010 May; 57(5):879-83. PubMed ID: 19765885
[TBL] [Abstract][Full Text] [Related]
51. Oral nitric oxide donors: a new pharmacological approach to detrusor-sphincter dyssynergia in spinal cord injured patients?
Reitz A; Knapp PA; Müntener M; Schurch B
Eur Urol; 2004 Apr; 45(4):516-20. PubMed ID: 15041118
[TBL] [Abstract][Full Text] [Related]
52. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?
Sahai A; Sangster P; Kalsi V; Khan MS; Fowler CJ; Dasgupta P
BJU Int; 2009 Mar; 103(5):630-4. PubMed ID: 18990156
[TBL] [Abstract][Full Text] [Related]
53. [Patient follow-up after botulinum toxin intradetrusor injection. Proposal for management in neurogenic patients].
de Sèze M; Ruffion A; Haab F; Chartier-Kastler E; Denys P; Game X; Karsenty G; Kerdraon J; Perrouin-Verbe B; Saussine C; Soler JM; Amarenco G
Ann Readapt Med Phys; 2008 May; 51(4):315-21. PubMed ID: 18514963
[TBL] [Abstract][Full Text] [Related]
54. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis.
Liu HT; Kuo HC
Urology; 2007 Sep; 70(3):463-8. PubMed ID: 17905097
[TBL] [Abstract][Full Text] [Related]
55. Effect of Botulinum Toxin A on Bladder Pain-Molecular Evidence and Animal Studies.
Yeh TC; Chen PC; Su YR; Kuo HC
Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32028597
[TBL] [Abstract][Full Text] [Related]
56. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.
Pannek J; Göcking K; Bersch U
BJU Int; 2009 Nov; 104(9):1246-50. PubMed ID: 19426192
[TBL] [Abstract][Full Text] [Related]
57. Treatment of detrusor external sphincter dyssynergia using ultrasound-guided trocar catheter transurethral botulinum toxin a injection in men with spinal cord injury.
Yang WX; Zhu HJ; Chen WG; Zhang DW; Su M; Feng JF; Liu CD; Cai P
Arch Phys Med Rehabil; 2015 Apr; 96(4):614-9. PubMed ID: 25450132
[TBL] [Abstract][Full Text] [Related]
58. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Antunes AA; Srougi M; Coelho RF; de Campos Freire G
Nat Clin Pract Urol; 2007 Mar; 4(3):155-60. PubMed ID: 17347660
[TBL] [Abstract][Full Text] [Related]
59. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
Gamé X; Castel-Lacanal E; Bentaleb Y; Thiry-Escudié I; De Boissezon X; Malavaud B; Marque P; Rischmann P
Eur Urol; 2008 Mar; 53(3):613-8. PubMed ID: 17804150
[TBL] [Abstract][Full Text] [Related]
60. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial.
Sahai A; Dowson C; Khan MS; Dasgupta P
BJU Int; 2009 Jun; 103(11):1509-15. PubMed ID: 19389019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
